n-methyl-3,4-methylenedioxyamphetamine has been researched along with Neurodevelopmental Disorders in 1 studies
N-Methyl-3,4-methylenedioxyamphetamine: An N-substituted amphetamine analog. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems. It is commonly referred to as MDMA or ecstasy.
3,4-methylenedioxymethamphetamine : A member of the class of benzodioxoles that is 1,3-benzodioxole substituted by a 2-(methylamino)propyl group at position 5.
Neurodevelopmental Disorders: These are a group of conditions with onset in the developmental period. The disorders typically manifest early in development, often before the child enters grade school, and are characterized by developmental deficits that produce impairments of personal, social, academic, or occupational functioning. (From DSM-5).
Excerpt | Relevance | Reference |
---|---|---|
" One of such drugs is MDMA (3,4-methylenedioxymethamphetamine) or ecstasy due to its high consumption in relevant age and sex groups and its adverse effects on human and rodent developing brains." | 2.66 | Developmental neurotoxicity of MDMA. A systematic literature review summarized in a putative adverse outcome pathway. ( Barenys, M; Fritsche, E; Gómez-Catalán, J; Masjosthusmann, S; Reverte, I, 2020) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (100.00) | 2.80 |
Authors | Studies |
---|---|
Barenys, M | 1 |
Reverte, I | 1 |
Masjosthusmann, S | 1 |
Gómez-Catalán, J | 1 |
Fritsche, E | 1 |
1 review available for n-methyl-3,4-methylenedioxyamphetamine and Neurodevelopmental Disorders
Article | Year |
---|---|
Developmental neurotoxicity of MDMA. A systematic literature review summarized in a putative adverse outcome pathway.
Topics: Adverse Outcome Pathways; Animals; Brain; Female; Humans; N-Methyl-3,4-methylenedioxyamphetamine; Ne | 2020 |